U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: TRUQAP
  1. Drug Approvals and Databases

Drug Trials Snapshots: TRUQAP

HOW TO USE THIS SNAPSHOT
The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT
Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the TRUQAP Prescribing Information for all the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).

TRUQAP (capivasertib)
(TRUE-cap)
AstraZeneca
Approval date: November 16, 2023


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

TRUQAP is an oral kinase inhibitor approved for use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

How is this drug used?

TRUQAP is an oral tablet given 400 mg orally twice daily (approximately 12 hours apart) with or without food, for four days followed by three days off treatment.

Who participated in the clinical trials?

The FDA approved TRUQAP based on safety and efficacy evidence from CAPItello-291, a study of 708 patients with advanced or metastatic HR-positive, HER2-negative breast cancer. This study was conducted at 181 sites in 19 countries in three different geographic regions worldwide: Region 1 includes the United States, Canada, Western Europe, Australia, and Israel; Region 2 includes Latin America, Eastern Europe, and Russia; and Region 3 includes Asia.

There were 44 patients enrolled in the United States, 21 in the TRUQAP arm and 23 in the placebo arm. The remaining 664 patients (94%) were enrolled outside the United States.

How were the trials designed?

TRUQAP was evaluated in a trial of 708 patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer following recurrence or progression on or after initial therapy. Patients were randomized to receive either TRUQAP or placebo, given orally twice daily for four days followed by three days off treatment each week of 28-day treatment cycle.

Efficacy was based on 289 patients with PIK3CA/AKT1/PTEN-alterations. The major efficacy outcomes were investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Additional efficacy outcome measures were overall survival (OS), investigator-assessed objective response rate (ORR), and duration of response (DoR).


DEMOGRAPHICS SNAPSHOT

Figure 1 summarizes how many male and female patients were enrolled in the clinical trial used to evaluate the efficacy of TRUQAP.

Figure 1. Baseline Demographics by Sex, Efficacy Population

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 2 (1%) male patients and 287 (99%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 2 summarizes how many patients by race were enrolled in the clinical trial used to evaluate the efficacy of TRUQAP.

Figure 2. Baseline Demographics by Race, Efficacy Population

Pie chart summarizing how many White, Black or African American, Asian, American Indian or Alaska Native, and other patients were in the clinical trial. In total, 151 (52%) White patients, 3 (1%) Black or African American patients, 83 (29%) Asian patients, 2 (1%) American Indian or Alaska Native patients, and 50 (17%) other patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 3 summarizes how many patients by age were enrolled in the clinical trial used to evaluate the efficacy of TRUQAP.

Figure 3. Baseline Demographics by Age, Efficacy Population

Pie chart summarizing how many patients by age were in the clinical trial. In total, 56 (19%) patients younger than 50 years of age, 143 (49%) patients between 50 and 64 years of age, 65 (23%) patients between 65 and 75 years of age, and 25 (9%) patients older than 75 years of age participated in the clinical trial.

Source: Adapted from FDA Review

Figure 4 summarizes how many patients by ethnicity were enrolled in the clinical trial used to evaluate the efficacy of TRUQAP.

Figure 4. Baseline Demographics by Ethnicity, Efficacy Population

Pie chart summarizing how many Hispanic and not Hispanic patients were in the clinical trial. In total, 24 (8%) Hispanic or Latino patients and 265 (92%) not Hispanic or Latino patients participated in the clinical trial.

Source: Adapted from FDA Review

What are the benefits of this drug?

A statistically significant difference in PFS was observed in the overall population and the efficacy population. An exploratory analysis of PFS in the 313 (44%) patients whose tumors did not have a PIK3CA/AKT1/PTEN-alteration showed a hazard ratio of 0.79 (95% CI:0.61, 1.02), indicating that the difference in the overall population was primarily attributed to the results seen in the efficacy population.

Were there any differences in how well the drug worked in clinical trials among sex, race, and age?

  • Sex: There was no biological rationale for a differential effect TRUQAP based on sex; however, there is not enough data to explore the efficacy results specifically in male patients.
  • Race: TRUQAP worked similarly in White, Asian, and Black or African American or other patients.
  • Age: TRUQAP worked similarly in patients younger and older than 65 years of age.
  • Ethnicity: TRUQAP showed a hazard ratio above 1 for the Hispanic or Latino patients while the hazard ratio was below 1 for the non-Hispanic patients; however, there were only 24 Hispanic patients enrolled (n=14 for the TRUQAP arm versus n=10 for the placebo arm) making the data difficult to interpret and no conclusions can be drawn.

What are the possible side effects?

TRUQAP carries Warnings and Precautions for high blood sugar, diarrhea, and skin reactions.

The most common side effects were diarrhea, skin reactions, fatigue, nausea, mouth sores, and vomiting.

Were there any differences in side effects among sex, race and age?

  • Sex: There is no biological rationale for a differential safety profile for TRUQAP based on sex; however, there is not enough data to explore the safety results specifically in male patients.
  • Race: There is no biological rationale for a differential safety profile for TRUQAP based on race; the safety of TRUQAP in patients with reported race of White (n=201), Asian (n=95), and all other races (n=59) was generally similar.
  • Age: The occurrence of side effects that were severe or led to changes in dosing was higher in patients 65 years of age or older. FDA’s independent analysis of the safety of TRUQAP comparing patients ≥65 years of age (n=115) to younger patients (n=240) receiving TRUQAP suggests a higher incidence of Grade 3 to 5 adverse reactions (57% versus 36%), dose reductions (30% versus 15%), dose interruptions (57% versus 30%), and permanent discontinuations (23% versus 8%), respectively.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

Back to Top